Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2026
Reporting Period: First Quarter ended March 31, 2026
Context: The filing announces the issuance of a press release regarding Q1 2026 financial results and schedules a conference call for May 5, 2026.
Key Financial Metrics
The provided Form 8-K text serves as a notification of results and does not contain specific financial data points. The actual figures are located in the referenced press release (Exhibit 99.1), which is not included in the input text.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains standard disclaimers regarding forward-looking statements (e.g., plans, strategies, intentions) which are subject to risks and uncertainties. The company explicitly states it undertakes no obligation to update these statements.
Risk Factors: Risks are referenced as being detailed in Item 1A of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed March 2, 2026).
Unusual Items: No unusual items are described in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2026) for actual Q1 2026 revenue, net income, and cash flow figures.
- Access the conference call webcast (archived on www.supernus.com) for management commentary on the results.
- Consult the Form 10-K filed on March 2, 2026 for the full list of risk factors referenced in this filing.
- Verify the forward-looking statements against actual performance in subsequent filings, noting the company's disclaimer on updating such statements.